



(51) International Patent Classification:

A61K 35/74 (2006.01) A61P 1/16 (2006.01)
A61K 35/66 (2006.01) A61P 29/00 (2006.01)

(21) International Application Number:

PCT/US2013/021752

(22) International Filing Date:

16 January 2013 (16.01.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/586,975 16 January 2012 (16.01.2012) US

(72) Inventor; and

(71) Applicant : MCKENNA, Elizabeth [US/US]; 5860
Langfield, Houston, Texas 77092 (US).

(74) Agents: RHODES, Monte R. et al.; Suite 900, Three
Riverway, Houston, Texas 77056 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

[Continued on next page]

(54) Title: COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEPATIC DISEASES AND DISORDERS

Human TLR/NLR Ligand Screening

Screening #1

TLR/NLR Cell Line	No Ligand	Lysate 1:100	Control
hTLR2	0.114	2.148	2.052
hTLR3	0.130	0.165	2.478
hTLR4/MD2-CD14	0.083	0.399	1.990
hTLR5	0.099	0.125	2.352
hTLR7	0.161	0.185	2.119
hTLR8	0.082	0.084	2.237
hTLR9	0.092	0.184	1.964
hNOD1	0.065	0.057	1.736
hNOD2	0.109	1.564	1.226

Screening #2

TLR/NLR Cell Line	No Ligand	Lysate 1:100	Control
hTLR2	0.098	2.173	2.046
hTLR3	0.116	0.169	2.428
hTLR4/MD2-CD14	0.140	0.303	1.848
hTLR5	0.093	0.121	2.347
hTLR7	0.158	0.160	2.093
hTLR8	0.083	0.042	2.278
hTLR9	0.144	0.186	2.083
hNOD1	0.070	0.058	1.765
hNOD2	0.172	1.049	1.393

Screening #3

TLR/NLR Cell Line	No Ligand	Lysate 1:100	Control
hTLR2	0.118	2.140	1.980
hTLR3	0.123	0.141	2.441
hTLR4/MD2-CD14	0.133	0.302	1.870
hTLR5	0.093	0.120	2.333
hTLR7	0.136	0.196	2.062
hTLR8	0.083	0.073	2.158
hTLR9	0.132	0.168	1.954
hNOD1	0.069	0.062	1.721
hNOD2	0.170	1.067	1.381

FIG. 5

(57) Abstract: The disclosure provides oral compositions and methods of using such compositions in treating subjects infected with one or more hepatic disorders. The compositions include lysates or cell wall extracts of one or more gram positive bacteria, exhibit particular activity against hepatitis C virus 5 (HCV), and may be useful in treating those infected with HCV as well as other hepatic diseases or disorders. Also described are methods of treating a hepatic disease or disorder by administering a therapeutically effective amount of at least one therapeutically active agent capable of upregulating or downregulating the Complement system pathway, wherein the 10 therapeutically active agent enhances the formation of one or more convertase enzymes.



-
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*